Randomized controlled trials have established the clinical efficacy and safety of infliximab in treating fistulizing Crohn disease (CD), and while evidence for adalimumab and vedolizumab in this indication is weaker, these drugs are also used in clinical practice, sometimes in treatment sequences of biologics, to treat fistulizing CD. In Europe, where access to biologic drugs is largely driven by budgetary considerations, biosimilars have the potential to improve access to treatment.
Randomized controlled trials have established the clinical efficacy and safety of infliximab in treating fistulizing Crohn disease (CD), and while evidence for adalimumab and vedolizumab in this indication is weaker, these drugs are also used in clinical practice, sometimes in treatment sequences of biologics, to treat fistulizing CD. In Europe, where access to biologic drugs is largely driven by budgetary considerations, biosimilars have the potential to improve access to treatment.
Authors of a study published in the United European Gastroenterology Journal developed a Markov model to compare the treatment sequences of 1, 2, and 3 biologic drugs, from the payer’s perspective, on a 5-year time horizon, with data on effectiveness and health state utilities obtained from the published literature. Country-specific costs (in Belgium, France, Germany, Hungary, Italy, the Netherlands, Spain, Sweden, and the United Kingdom), and both official list prices and estimated real prices for the drugs, were taken into consideration.
When considering the use of single biologics at list price versus standard (non-biologic) treatment:
In treatment sequences involving 2 to 3 biologics, based on list price, adding a second biologic to the treatment sequence after biosimilar infliximab provided additional QALY gains (0.103—0.133) compared to the biosimilar infliximab alone, but at larger additional costs (€6129–€18,700, or approximately $7588-$23,150), with adalimumab being more cost-effective than vedolizumab as a second agent. Adding a third agent (vedolizumab) to biosimilar infliximab and adalimumab provided additional QALY gains (0.113-0.120) at larger additional costs (€10,444-€17,587, or approximately $12,929-$21,772) in most countries.
When considering a real price at a 30% discount to the list price of infliximab and biosimilar infliximab—and a 20% decrease for adalimumab—in each country, the researchers observed a 19% to 30% decrease in the ICERs for biosimilar infliximab (€24,364-€56,086, or approximately $30,162-$69,433) per QALY compared with standard care. The ICER of the biosimilar infliximab—adalimumab treatment sequence decreased by 20% to 22% (€45,513-€105,875, or approximately $56,344-$131,070) per QALY.
The authors conclude that the first choice of biologic treatment for fistulizing CD should be biosimilar infliximab. In the case of treatment failure, a switch to adalimumab or vedolizumab would provide meaningful health benefits, but at increased costs.
Reference
Baji P, Gulácsi L, Brodszky V, et al. Cost-effectiveness of biological treatment sequences for fistulising Crohn’s disease across Europe. United European Gastroenterol J. 2018;6(2):310-321. doi: 10.1177/2050640617708952.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.